Compass Pathways PLC Sponsored ADR $CMPS Stock Position Boosted by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 23.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 399,506 shares of the company’s stock after purchasing an additional 76,297 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Compass Pathways were worth $4,970,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Compass Pathways in the third quarter valued at about $85,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Compass Pathways by 15.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 24,432 shares of the company’s stock worth $317,000 after buying an additional 3,249 shares during the period. North Star Investment Management Corp. boosted its position in shares of Compass Pathways by 23.9% during the third quarter. North Star Investment Management Corp. now owns 9,317 shares of the company’s stock worth $116,000 after buying an additional 1,800 shares during the period. Mount Vernon Associates Inc. MD grew its holdings in shares of Compass Pathways by 19.7% during the third quarter. Mount Vernon Associates Inc. MD now owns 45,500 shares of the company’s stock worth $566,000 after buying an additional 7,500 shares in the last quarter. Finally, Maxi Investments CY Ltd bought a new position in shares of Compass Pathways during the third quarter worth about $1,070,000. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Stock Up 10.2%

NASDAQ CMPS traded up $0.80 during trading hours on Friday, hitting $8.61. 3,757,104 shares of the company traded hands, compared to its average volume of 3,011,761. The business’s 50-day moving average is $12.32 and its 200-day moving average is $10.41. Compass Pathways PLC Sponsored ADR has a twelve month low of $4.88 and a twelve month high of $15.87. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30. The stock has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.47 and a beta of 2.43.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.08. Sell-side analysts anticipate that Compass Pathways PLC Sponsored ADR will post -0.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CMPS. Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Compass Pathways in a research report on Tuesday. Morgan Stanley lifted their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Wall Street Zen lowered shares of Compass Pathways from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 31st. BTIG Research restated a “buy” rating and set a $25.00 target price on shares of Compass Pathways in a report on Tuesday. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Compass Pathways in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.14.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.